Phase Ib Pilot Study Of Itacitinib With Alemtuzumab In Patients With T-Cell Prolymphocytic Leukemia (T-Pll)
MD Anderson Study Status
This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
For general questions about clinical trials: